Postherpetic neuralgia (PHN) has served—and continues to serve—as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer’s Lyrica (pregabalin), gabapentin (Pfizer’s Neurontin, generics), and the 5% lidocaine patch (Endo/Grünenthal’s Lidoderm/Versatis, generics) all capitalized on their approvals for PHN in the United States and Europe to achieve wider commercial success in the treatment of other forms of NP, such as neuropathic back pain and postsurgical/post-trauma NP. Despite the availability of multiple generic analgesics and well-established treatments for PHN, the substantial percentage of patients refractory to treatment, the high rate of polypharmacy, and the large unmet need associated with pain treatment make PHN—and NP overall—an area of commercial opportunity.

Table of contents

  • Neuropathic Pain - Unmet Need - Detailed Expanded Analysis Postherpetic Neuralgia

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.

Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.

Related Reports

Neuropathic Pain - Landscape & Forecast - Disease Landscape & Forecast

The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid a...

View Details